250,000 shares bought on the open, page-3

There's a lot to like TB. Probably one of the most sophisticated lab-to-patient biotech plays on the ASX. They're carving out space in a number of markets. Some are quite active, a couple are underserved and there is also a bit of blue sky. Founder has long been telling the market that when they get traction, they will attract the attention of the global players and will be on the block.

I have no doubt he has been seeding this exit strategy with the big boys from the get go. All Telix need do is deliver regulatory results and demonstrate payer willingness. After that, they can pick and chose from suitors with fat checkbooks. If you believe the founder, then $2bn is a number to keep in mind. Long way to go.